103 related articles for article (PubMed ID: 33222758)
1. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology.
Yumeen S; Mirza FN; Lewis JM; Girardi M
J Invest Dermatol; 2020 Dec; 140(12):2319-2325.e1. PubMed ID: 33222758
[TBL] [Abstract][Full Text] [Related]
2. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
[TBL] [Abstract][Full Text] [Related]
3. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
4. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
[TBL] [Abstract][Full Text] [Related]
5. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
O'Neil J; Benita Y; Feldman I; Chenard M; Roberts B; Liu Y; Li J; Kral A; Lejnine S; Loboda A; Arthur W; Cristescu R; Haines BB; Winter C; Zhang T; Bloecher A; Shumway SD
Mol Cancer Ther; 2016 Jun; 15(6):1155-62. PubMed ID: 26983881
[TBL] [Abstract][Full Text] [Related]
6. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. Evaluating response to antineoplastic drug combinations in tissue culture models.
Reynolds CP; Maurer BJ
Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Schaffer M; Chaturvedi S; Davis C; Aquino R; Stepanchick E; Versele M; Liu Y; Yang J; Lu R; Balasubramanian S
Leuk Lymphoma; 2018 Apr; 59(4):931-940. PubMed ID: 28750570
[TBL] [Abstract][Full Text] [Related]
10. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
11. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
12. Preclinical modeling of combination treatments: fantasy or requirement?
Decker S; Sausville EA
Ann N Y Acad Sci; 2005 Nov; 1059():61-9. PubMed ID: 16382044
[TBL] [Abstract][Full Text] [Related]
13. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.
Wali VB; Langdon CG; Held MA; Platt JT; Patwardhan GA; Safonov A; Aktas B; Pusztai L; Stern DF; Hatzis C
Cancer Res; 2017 Jan; 77(2):566-578. PubMed ID: 27872098
[TBL] [Abstract][Full Text] [Related]
14. A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments.
Kuo CT; Wang JY; Lu SR; Lai YS; Chang HH; Hsieh JT; Wo AM; Chen BPC; Lu JH; Lee H
Sci Rep; 2019 Jul; 9(1):10120. PubMed ID: 31300742
[TBL] [Abstract][Full Text] [Related]
15. Assessing combinations of cytotoxic agents using leukemia cell lines.
Reynolds CP; Kang MH; Keshelava N; Maurer BJ
Curr Drug Targets; 2007 Jun; 8(6):765-71. PubMed ID: 17584032
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Inaba K; Oda K; Aoki K; Sone K; Ikeda Y; Miyasaka A; Kashiyama T; Fukuda T; Makii C; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Oncotarget; 2016 May; 7(20):29577-91. PubMed ID: 27102436
[TBL] [Abstract][Full Text] [Related]
17. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
18. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.
Rickles RJ; Pierce LT; Giordano TP; Tam WF; McMillin DW; Delmore J; Laubach JP; Borisy AA; Richardson PG; Lee MS
Blood; 2010 Jul; 116(4):593-602. PubMed ID: 20382846
[TBL] [Abstract][Full Text] [Related]
20. A microfluidics platform for combinatorial drug screening on cancer biopsies.
Eduati F; Utharala R; Madhavan D; Neumann UP; Longerich T; Cramer T; Saez-Rodriguez J; Merten CA
Nat Commun; 2018 Jun; 9(1):2434. PubMed ID: 29934552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
